OCM
KYMR icon

Ovata Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Ovata Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-500
Closed -$16K – 62
2020
Q3 		$16K Buy
+500
New +$15.3K 0.01% 63

Other funds holding KYMR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DIC
Deer IX & Co Larchmont, New York $971M AUM 24.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ovata Capital Management's KYMR Position: Q4 2020 in Review

Ovata Capital Management sold out of Kymera Therapeutics (KYMR) in Q4 2020, closing a stake of 500 shares — an estimated $16K sold.

Ovata Capital Management first reported a position in KYMR in Q3 2020 and held it in 1 quarter. The position peaked at $16K in Q3 2020. 75 funds tracked by Wall St. Rank hold KYMR as of Q4 2020.

  • Ovata Capital Management reported no remaining Kymera Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Ovata Capital Management sold 500 Kymera Therapeutics shares in Q4 2020, an estimated $16K.
  • Ovata Capital Management first reported a position in Kymera Therapeutics in Q3 2020 and held it in 1 quarter.
  • Ovata Capital Management's Kymera Therapeutics position peaked at $16K in Q3 2020.
  • 75 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2020.

Based on Ovata Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.